DK2653552T3 - SCREENINGSMETODE VED ANVENDELSE AF GELATINASE-MEDIERET EphA4-SPALTNINGSREAKTION SOM INDIKATOR - Google Patents

SCREENINGSMETODE VED ANVENDELSE AF GELATINASE-MEDIERET EphA4-SPALTNINGSREAKTION SOM INDIKATOR Download PDF

Info

Publication number
DK2653552T3
DK2653552T3 DK11848175.3T DK11848175T DK2653552T3 DK 2653552 T3 DK2653552 T3 DK 2653552T3 DK 11848175 T DK11848175 T DK 11848175T DK 2653552 T3 DK2653552 T3 DK 2653552T3
Authority
DK
Denmark
Prior art keywords
val
ser
ala
gly
leu
Prior art date
Application number
DK11848175.3T
Other languages
English (en)
Inventor
Eiji Inoue
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of DK2653552T3 publication Critical patent/DK2653552T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (9)

1. In vitro-fremgangsmåde til screening for et stof, der påvirker gelatinase-medieret Eph-receptor-A4-spaltning, som omfatter trinene: (a) etablering af kontakt mellem en første biologisk sammensætning, der indeholder gelatinase, og en anden biologisk sammensætning, der indeholder EphA4, ved tilstedeværelse og fravær af et kandidatstof; (b) måling af tilstedeværelse eller mængden af EphA4-ektodomæne- og/eller endodomænefragmentet; og (c) selektion af kandidatstoffet som et stof, der påvirker gelatinase-medieret EphA4-spaltning, hvis resultaterne i trin (b) målt i nærvær af kandidatstoffet er ændret i forhold til resultaterne i trin (b) målt i fravær af kandidatstoffet.
2. Fremgangsmåde ifølge krav 1, hvor trin (c) omfatter identificering af kandidatstoffet som et stof, der fremmer gelatinase-medieret EphA4-spaltning, hvis EphA4-endodomæne-og/eller ektodomænefragmentet målt i nærvær af kandidatstoffet i trin (b) er forøget sammenlignet med EphA4-endodomæne-og/eller ektodomænefragmentet målt i fravær af kandidatstoffet i trin (b).
3. Fremgangsmåde ifølge krav 1, hvor trin (c) omfatter identificering af kandidatstoffet som et stof, der hæmmer gelatinase-medieret EphA4-spaltning, hvis EphA4-endodomæne-og/eller ektodomænefragmentet målt i nærvær af kandidatstoffet i trin (b) er reduceret sammenlignet med EphA4-endodomæne-og/eller ektodomænefragmentet målt i fravær af kandidatstoffet i trin (b).
4. Fremgangsmåde ifølge krav 2, hvor stoffet, der fremmer gelatinase-medieret EphA4-spaltning, yderligere evalueres som et stof, der fremmer γ-secretase-medieret EphA4-spaltningsreaktion.
5. Fremgangsmåde ifølge krav 3, hvor stoffet, der hæmmer gelatinase-medieret EphA4-spaltning, yderligere evalueres som et stof, der hæmmer γ-secretase-medieret EphA4-spaltningsreaktion.
6. Fremgangsmåde ifølge krav 2, hvor stoffet, der fremmer gelatinase-medieret EphA4-spaltning, yderligere evalueres som et stof, der fremmer spina-dannelsesreaktion medieret af det intracellulære EphA4-fragment.
7. Fremgangsmåde ifølge krav 3, hvor stoffet, der hæmmer gelatinase-medieret EphA4-spaltning, yderligere evalueres som et stof, der hæmmer spina-dannelsesreaktion medieret af det intracellulære EphA4-fragment.
8. Anvendelse af gelatinase til spaltning af ektodomænet af EphA4.
9. Anvendelse af et analysekit, der omfatter en første biologisk sammensætning, der indeholder gelatinase, og en anden biologisk sammensætning, der indeholder EphA4, til måling af gelatinase-medieret EphA4-spaltning.
DK11848175.3T 2010-12-17 2011-12-08 SCREENINGSMETODE VED ANVENDELSE AF GELATINASE-MEDIERET EphA4-SPALTNINGSREAKTION SOM INDIKATOR DK2653552T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010282165 2010-12-17
PCT/JP2011/078460 WO2012081502A1 (ja) 2010-12-17 2011-12-08 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法

Publications (1)

Publication Number Publication Date
DK2653552T3 true DK2653552T3 (da) 2017-01-16

Family

ID=46244607

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11848175.3T DK2653552T3 (da) 2010-12-17 2011-12-08 SCREENINGSMETODE VED ANVENDELSE AF GELATINASE-MEDIERET EphA4-SPALTNINGSREAKTION SOM INDIKATOR

Country Status (5)

Country Link
US (1) US8865426B2 (da)
EP (1) EP2653552B1 (da)
JP (1) JP6059017B2 (da)
DK (1) DK2653552T3 (da)
WO (1) WO2012081502A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5961608B2 (ja) * 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
JP6811706B2 (ja) * 2014-07-31 2021-01-13 ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
WO2017043466A1 (ja) 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
JP6877419B2 (ja) * 2015-10-27 2021-05-26 ザ ユニバーシティー オブ クイーンズランド 治療の方法およびそのために有用な剤
AR119303A1 (es) * 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
KR20230123923A (ko) * 2020-12-24 2023-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 항-EphA4 항체
CA3195085A1 (en) * 2020-12-24 2022-06-30 Eisai R&D Management Co., Ltd. Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2824433B2 (ja) 1988-12-09 1998-11-11 財団法人化学及血清療法研究所 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター
AU629554B2 (en) 1988-06-24 1992-10-08 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Exogenous gene expression vector containing chick beta-actin gene promoter
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5902732A (en) 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US20020068361A1 (en) 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
US20070026409A1 (en) 2001-08-14 2007-02-01 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
JP2003169699A (ja) 2001-12-10 2003-06-17 Japan Science & Technology Corp 特異的γプロテアーゼ阻害剤のスクリーニング方法
JP2004000060A (ja) 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
HRP20050461A2 (en) 2002-11-26 2005-08-31 Pharmacia & Upjohn Company Llc Soluble notch-based substrates for gamma secretase and methods and compositions for using same
WO2005045028A1 (ja) 2003-11-10 2005-05-19 Osaka Industrial Promotion Organization セル・フリー・Ｎｏｔｃｈ切断分析方法及び薬剤スクリーニング方法
TW200538739A (en) 2004-02-27 2005-12-01 Oncotherapy Science Inc EphA4 as therapeutic target of PRC and PDACa
CA2579352A1 (en) 2004-09-08 2006-03-16 The University Of Queensland Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
GB0427023D0 (en) 2004-12-09 2005-01-12 Merck Sharp & Dohme Assay method
EP1947193A1 (en) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
US7910324B2 (en) 2007-06-08 2011-03-22 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the processing of EphA4 by γ-secretase
CA2692604A1 (en) 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
US20090191580A1 (en) 2007-07-19 2009-07-30 Eisai R & D Management Co., Ltd. METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE
JPWO2009017234A1 (ja) 2007-08-01 2010-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ｃ−Ｒｅｔを利用したスクリーニング方法
US20090163594A1 (en) 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
JP5580598B2 (ja) 2007-11-15 2014-08-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ＥｐｈＡ７を利用したスクリーニング方法
US7892769B2 (en) 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Also Published As

Publication number Publication date
EP2653552A1 (en) 2013-10-23
US20130288278A1 (en) 2013-10-31
WO2012081502A1 (ja) 2012-06-21
EP2653552A4 (en) 2014-08-20
EP2653552B1 (en) 2016-10-19
US8865426B2 (en) 2014-10-21
JP6059017B2 (ja) 2017-01-11
JPWO2012081502A1 (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
EP2166110B1 (en) Screening method utilizing novel substrate epha4 for gamma-secretase
DK2653552T3 (da) SCREENINGSMETODE VED ANVENDELSE AF GELATINASE-MEDIERET EphA4-SPALTNINGSREAKTION SOM INDIKATOR
EP2223999B1 (en) Epha4 polypeptide having novel activity and use thereof
US8530181B2 (en) Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
EP2177623A1 (en) METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE
CA2375450C (en) Screening methods for altering circadian rhythm proteins
US20100190184A1 (en) Screening method utilizing novel substrate c-ret for gamma-secretase
Schöbel et al. Expression cloning screen for modifiers of amyloid precursor protein shedding
KR20050085177A (ko) 감마 세크레타제를 위한 가용성 노치-기초 기질, 및 이를사용하는 조성물 및 방법
US6709839B1 (en) SYK-UBP proteins, compositions and methods of use
US6890725B2 (en) Modulators of B-lymphocyte activation, myosin-1F compositions and methods of use
JP2012039882A (ja) γ−セクレターゼの新規基質ＰｌｅｘｉｎＡ４を利用したスクリーニング方法
JP2012039881A (ja) γ−セクレターゼの新規基質ＰｌｅｘｉｎＡ２を利用したスクリーニング方法
CA2385879A1 (en) Traf4 associated cell cycle proteins, compositions and methods of use